Methods of increasing lean tissue mass using OB protein compositions
First Claim
1. A process of producing a fusion protein comprising an Fc portion of an antibody attached at the N-terminus of an OB protein moiety, wherein the process comprises expressing a DNA sequence comprising:
- (a) a first nucleic acid sequence encoding said Fc portion of an antibody; and
(b) a second nucleic acid sequence encoding said OB protein moiety selected from the group consisting of;
(i) a nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID. NO;
2 or the amino acid sequence set forth in SEQ ID NO;
4;
(ii) a nucleic acid sequence encoding the amino acid sequence set forth in SEQ. ID. NO;
4 having a lysine residue at position 35 and an isoleucine residue at position 74 according to the position numbering designation set forth in SEQ. ID. NO;
4;
(iii) a nucleic acid sequence encoding the amino acid sequence of subpart (i), lacking a glutaminyl residue at position 28; and
(iv) a nucleic acid sequence encoding the amino acid sequence of subpart (i), wherein the methionyl residue at the N-terminus is absent.
1 Assignment
0 Petitions
Accused Products
Abstract
DNA sequences comprising nucleic acids encoding fusion proteins comprising an Fc portion of an antibody attached at the N-terminus of an OB protein moiety, vectors comprising such DNA sequences, host cells comprising such vectors or DNA sequences, and processes for preparing such fusion proteins, and pharmaceutical compositions comprising such fusion proteins, are described. The DNA sequences, vectors comprising such DNA sequences, host cells comprising such vectors or DNA sequences, and processes for preparing such fusion proteins, and pharmaceutical compositions comprising such fusion proteins are useful, for example, in providing therapeutically effective amounts of compositions useful for, for example, increasing insulin sensitivity, decreasing the dose of insulin required for the treatment of diabetes, controlling serum glucose levels, increasing lean tissue mass, increasing overall body strength, or regulating bone resorption, or effecting any combination of such, in subjects in need or desirous thereof to which the compositions are administered.
27 Citations
13 Claims
-
1. A process of producing a fusion protein comprising an Fc portion of an antibody attached at the N-terminus of an OB protein moiety, wherein the process comprises expressing a DNA sequence comprising:
-
(a) a first nucleic acid sequence encoding said Fc portion of an antibody; and (b) a second nucleic acid sequence encoding said OB protein moiety selected from the group consisting of; (i) a nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID. NO;
2 or the amino acid sequence set forth in SEQ ID NO;
4;(ii) a nucleic acid sequence encoding the amino acid sequence set forth in SEQ. ID. NO;
4 having a lysine residue at position 35 and an isoleucine residue at position 74 according to the position numbering designation set forth in SEQ. ID. NO;
4;(iii) a nucleic acid sequence encoding the amino acid sequence of subpart (i), lacking a glutaminyl residue at position 28; and (iv) a nucleic acid sequence encoding the amino acid sequence of subpart (i), wherein the methionyl residue at the N-terminus is absent. - View Dependent Claims (2, 5)
-
-
3. A vector comprising a DNA sequence, wherein said DNA sequence comprises:
-
(a) a first nucleic acid encoding said c portion of an antibody; and (b) a second nucleic acid sequence encoding said OB protein moiety selected from the group consisting of; (i) a nucleic acid sequence encoding the amino acid sequence set forth in SEQ ID. NO;
2 or the amino acid sequence set forth in SEQ ID NO;
4;(ii) a nucleic acid sequence encoding the amino acid sequence set forth in SEQ. ID. NO;
4 having a lysine residue at position 35 and an isoleucine residue at position 74 according to the position numbering designation set forth in SEQ. ID. NO;
4;(iii) a nucleic acid sequence encoding the amino acid sequence of subpart (i) lacking a glutaminyl residue at position 28; and (iv) a nucleic acid sequence encoding the amino acid sequence of subpart (i) wherein the methionyl residue at the N-terminus is absent. - View Dependent Claims (4, 6, 7, 8, 9, 10, 11, 12, 13)
-
Specification